Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression
Authors:
- Gennie L. ParkmanGPGennie L. Parkman
- Tursun TurapovTTTursun Turapov
- David A. KircherDKDavid A. Kircher
- William J. BurnettWBWilliam J. Burnett
- Christopher M. StehnCSChristopher M. Stehn
- Kayla O'TOoleKOKayla O'TOole
- Katie M. CulverKCKatie M. Culver
- Ashley T. ChadwickACAshley T. Chadwick
- Riley C. ElmerRERiley C. Elmer
- Ryan FlahertyRFRyan Flaherty
- Karly A. StanleyKSKarly A. Stanley
- Mona FothMFMona Foth
- 3 November 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (3) , 301-315
Abstract
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo. Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.Keywords
All Related Versions
Funding Information
- National Cancer Institute (F31CA254307)
- National Cancer Institute (T32CA265782)
- National Cancer Institute (R01CA121118)
- National Cancer Institute (R01CA176839)
- National Cancer Institute (P30CA042014)
This publication has 48 references indexed in Scilit:
- Discovery of an AKT Degrader with Prolonged Inhibition of Downstream SignalingCell Chemical Biology, 2020
- Oncogenic Signaling Pathways in The Cancer Genome AtlasCell, 2018
- AKT/PKB Signaling: Navigating the NetworkCell, 2017
- SGK12017
- AKT1 Activation Promotes Development of Melanoma MetastasesCell Reports, 2015
- mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma FormationCancer Cell, 2015
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaCancer Chemotherapy and Pharmacology, 2014
- The emerging multiple roles of nuclear AktBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- mTOR-Raptor Binds and Activates SGK1 to Regulate p27 PhosphorylationMolecular Cell, 2008
- Rapamycin and mTOR kinase inhibitorsJournal of Chemical Biology, 2008